Literature DB >> 7949087

Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin.

F Bex1, P Hermans, S Sprecher, A Achour, R Badjou, C Desgranges, J Cogniaux, P Franchioli, C Vanhulle, A Lachgar.   

Abstract

Immunotherapy by adoptive transfer of lymphocytes was attempted in identical twins, one who was virus-free and the other who was infected with human immunodeficiency virus-1 (HIV-1), at the stage of acquired immunodeficiency syndrome. The noninfected twin was vaccinated by priming with a recombinant vaccinia virus expressing the envelope glycoprotein of one of his brother's viruses and boosting with the same purified gp160 adsorbed on alum. Vaccination elicited major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes specific for HIV-1, but no antibody response. The diseased brother, a 38-year-old homosexual who had developed repeated opportunistic infections since 1990 and had a CD4+ count reduced to practically zero, was treated by infusions of lymphocytes collected from the vaccinated brother by lymphopheresis. After a first transfer of the whole lymphocyte population, no changes were observed in the clinical status and biologic or virologic parameters. A second transfer was then applied with activation of the cells with purified envelope glycoprotein before infusion. The outcome of the treatment was an increase in total lymphocytes, in CD4+ and activated CD8+ DR+ cell counts, and in proliferative responses to HIV antigens. A marked but transient 3-log increase in cellular and plasmatic virus loads was also observed after the second adoptive transfer. These observations will be considered with attention to improve the future adoptive transfer protocols, especially in patients with severe CD4+ depletion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949087

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 2.  Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.

Authors:  G Hütter; J A Zaia
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

Review 3.  Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.

Authors:  Benjamin J Burwitz; Justin M Greene; David H O'Connor
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

Review 4.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

5.  Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals.

Authors:  A Achour; F Bex; P Hermans; A Burny; D Zagury
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide.

Authors:  Ammar Achour; Jean-Michel Biquard; Velibor Krsmanovic; Jean-Pierre M'bika; Damien Ficheux; Marianna Sikorska; Alain J Cozzone
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

7.  Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques.

Authors:  Justin M Greene; Benjamin J Burwitz; Alex J Blasky; Teresa L Mattila; Jung Joo Hong; Eva G Rakasz; Roger W Wiseman; Kim J Hasenkrug; Pamela J Skinner; Shelby L O'Connor; David H O'Connor
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.